author profile photo

Roberto Vendramin

University College London - UCL Cancer Institute

Senior postdoctoral research fellow

Gower Street

London, WC1E 6BT

United States

The Francis Crick Institute

Visiting scientist

1 Midland Road

London, NW1 1AT

United Kingdom

http://www.crick.ac.uk/research/labs/charles-swanton

SCHOLARLY PAPERS

2

DOWNLOADS

277

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Pharmacologic Inhibition of Nonsense-Mediated Decay Induces Anti-Tumour Immunogenicity in Ex Vivo Patient Tumours

Number of pages: 65 Posted: 16 Feb 2024
University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, Weizmann Institute of Science, Weizmann Institute of Science, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, Genesis Therapeutics, Inc., University College London - Cancer Immunology Unit, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, University College London - Research Department of Hematology, University College London - UCL Cancer Institute, University College London - UCL Cancer Institute, The Francis Crick Institute, The Hebrew University of Jerusalem, University College London - UCL Cancer Institute, Independent, The Francis Crick Institute, Genesis Therapeutics, Inc., University College London - Cancer Immunology Unit, University College London - UCL Cancer Institute, Weizmann Institute of Science, The Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, University College London - UCL Cancer Institute and Independent
Downloads 206 (369,861)
Citation 1

Abstract:

Loading...

Nonsense-mediated decay, SMG1, cancer, anti-tumour immunogenicity, neoantigens, frameshift insertions/deletions, patient-derived fragments.

2.

The Generation of Cancer-Specific Ribosomes by the lncRNA LISR Suppresses Melanoma Anti-Tumour Immunity

Number of pages: 665 Posted: 05 May 2023
KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology, University College London - UCL Cancer Institute, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology, European Institute of Oncology (IEO) IRCCS, KU Leuven - Laboratory for Molecular Cancer Biology, KU Leuven - Laboratory for Cytogenetics and Genome Research, TransCure bioServices, UZ Leuven Hospitals - epartment of General Medical Oncolog, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Rega Institute for Medical Research, KU Leuven - Laboratory for RNA Cancer Biology, KU Leuven - Laboratory for RNA Cancer Biology and Independent
Downloads 71 (883,195)

Abstract:

Loading...

Melanoma, Therapy resistance, ICB, lncRNA, ISR